Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?

Xunrong Luo, Kevan C. Herold, Stephen D. Miller*

*Corresponding author for this work

Research output: Contribution to journalReview article

99 Scopus citations

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic β cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by " tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing β cells from endogenous progenitors.

Original languageEnglish (US)
Pages (from-to)488-499
Number of pages12
JournalImmunity
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2010

    Fingerprint

Keywords

  • Cellimmuno
  • Humdisease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this